Nextage Therapeutics (Israel) Buy Hold or Sell Recommendation
| MCTC Stock | ILA 71.90 2.00 2.71% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Nextage Therapeutics is 'Strong Sell'. Macroaxis provides Nextage Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MCTC positions.
Check out Nextage Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Nextage and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Nextage Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Nextage |
Execute Nextage Therapeutics Buy or Sell Advice
The Nextage recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nextage Therapeutics. Macroaxis does not own or have any residual interests in Nextage Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nextage Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Nextage Therapeutics Trading Alerts and Improvement Suggestions
| Nextage Therapeutics had very high historical volatility over the last 90 days | |
| The company has 0.0 in debt which may indicate that it relies heavily on debt financing | |
| The company has a current ratio of 0.43, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Nextage Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nextage Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nextage Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nextage to invest in growth at high rates of return. When we think about Nextage Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Nextage Therapeutics reported the revenue of 297 K. Net Loss for the year was (2.09 M) with profit before overhead, payroll, taxes, and interest of 207 K. | |
| Nextage Therapeutics has accumulated about 358 K in cash with (5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders |
Nextage Therapeutics Returns Distribution Density
The distribution of Nextage Therapeutics' historical returns is an attempt to chart the uncertainty of Nextage Therapeutics' future price movements. The chart of the probability distribution of Nextage Therapeutics daily returns describes the distribution of returns around its average expected value. We use Nextage Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Nextage Therapeutics returns is essential to provide solid investment advice for Nextage Therapeutics.
| Mean Return | 0.21 | Value At Risk | -8.77 | Potential Upside | 12.00 | Standard Deviation | 6.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Nextage Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Nextage Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nextage Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nextage Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nextage stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.04 | |
β | Beta against Dow Jones | 2.01 | |
σ | Overall volatility | 5.08 | |
Ir | Information ratio | 0.01 |
Nextage Therapeutics Volatility Alert
Nextage Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Nextage Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Nextage Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Nextage Therapeutics Fundamentals Vs Peers
Comparing Nextage Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nextage Therapeutics' direct or indirect competition across all of the common fundamentals between Nextage Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nextage Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nextage Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Nextage Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nextage Therapeutics to competition |
| Fundamentals | Nextage Therapeutics | Peer Average |
| Return On Asset | -0.37 | -0.14 |
| Profit Margin | (2.30) % | (1.27) % |
| Operating Margin | (9.71) % | (5.51) % |
| Shares Outstanding | 2.27 M | 571.82 M |
| Shares Owned By Insiders | 22.39 % | 10.09 % |
| Shares Owned By Institutions | 0.02 % | 39.21 % |
| Price To Earning | (91.98) X | 28.72 X |
| Price To Book | 4.68 X | 9.51 X |
| Price To Sales | 26.11 X | 11.42 X |
| Revenue | 297 K | 9.43 B |
| Gross Profit | 207 K | 27.38 B |
| EBITDA | (5.38 M) | 3.9 B |
| Net Income | (2.09 M) | 570.98 M |
| Cash And Equivalents | 358 K | 2.7 B |
| Cash Per Share | 0.16 X | 5.01 X |
| Debt To Equity | 65.70 % | 48.70 % |
| Current Ratio | 0.44 X | 2.16 X |
| Book Value Per Share | 0.90 X | 1.93 K |
| Cash Flow From Operations | (5 M) | 971.22 M |
| Earnings Per Share | (0.24) X | 3.12 X |
| Number Of Employees | 6 | 18.84 K |
| Beta | 1.05 | -0.15 |
| Market Capitalization | 9.54 M | 19.03 B |
| Total Asset | 6.01 M | 29.47 B |
| Retained Earnings | (103 M) | 9.33 B |
| Working Capital | 1000 K | 1.48 B |
| Current Asset | 3 M | 9.34 B |
| Current Liabilities | 2 M | 7.9 B |
| Z Score | -23.8 | 8.72 |
| Net Asset | 6.01 M |
Nextage Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nextage . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Nextage Therapeutics Buy or Sell Advice
When is the right time to buy or sell Nextage Therapeutics? Buying financial instruments such as Nextage Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nextage Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Materials Thematic Idea Now
Construction Materials
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.